What is the 13F Pro Quality Score for CVS?

13F Pro ranks CVS HEALTH Corp (CVS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CVS's current score at https://13fpro.ai/research/CVS (free sign-up required for the full ranking).

Which hedge funds own the most CVS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CVS include BlackRock,, VANGUARD CAPITAL MANAGEMENT, Capital World Investors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CVS as soon as new 13F filings post.

Where does 13F Pro source CVS data?

All CVS HEALTH Corp fundamentals and ownership data come directly from SEC EDGAR. CVS HEALTH Corp files with the SEC under CIK 64803. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CVS in?

CVS HEALTH Corp (CVS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CVS research updated on 13F Pro?

CVS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CVS HEALTH Corp(CVS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 64803 CVS stock profile & AI dashboard →

13F Pro Quality Score

51.3/100

Rank #1,404 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

54.7/100

Profitability

36.0/100

Balance Sheet

40.9/100

Earnings Quality

4.2/100

Free Cash Flow

41.1/100

Institutional Flow

27.4/100

Revenue Scale

99.8/100

Dilution Risk

87.3/100

CVS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CVS HEALTH Corp (CVS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CVS at 51.3/100 on a 32-signal composite quality model, placing it at rank #1,404 of 2,879 stocks — the top half of the AI-ranked universe. CVS scores in the top quartile across revenue scale (99.8). Areas of concern include earnings quality (4.2) and institutional flow (27.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), CVS HEALTH Corp reports quarterly revenue of $100.4B, net income of $2.9B, an operating margin of 4.7%. Top institutional holders of CVS by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, Capital World Investors, based on the most recent SEC filings. CVS trades on the NYSE exchange and files with the SEC under CIK 64803. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CVS HEALTH Corp directly from SEC EDGAR. CVS HEALTH Corp's 13F Pro composite quality score has ranged between 8 and 66 since 2021, currently 51.3 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$100.4B

Net Income

Q1 2026

$2.9B

Free Cash Flow

Q1 2026

$3.4B

Operating Margin

Q1 2026

4.7%

ROIC

Q1 2026

3.4%

D/E Ratio

Q1 2026

0.81

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+7.8% YoY

$402.07BFY 2025

FY22 $322.47BFY23 $357.78BFY24 $372.81BFY25 $402.07B

Net Income

-61.7% YoY

$1.77BFY 2025

FY22 $4.31BFY23 $8.34BFY24 $4.61BFY25 $1.77B

Operating Income

-45.3% YoY

$4.66BFY 2025

FY22 $7.95BFY23 $13.74BFY24 $8.52BFY25 $4.66B

EPS (Diluted)

-62.0% YoY

$1.39FY 2025

FY22 $3.26FY23 $6.47FY24 $3.66FY25 $1.39

Total Assets

+0.1% YoY

$253.54BFY 2025

FY22 $228.28BFY23 $249.73BFY24 $253.22BFY25 $253.54B

Total Debt

-2.6% YoY

$64.57BFY 2025

FY22 $52.25BFY23 $61.61BFY24 $66.27BFY25 $64.57B

Op. Cash Flow

+16.8% YoY

$10.64BFY 2025

FY22 $16.18BFY23 $13.43BFY24 $9.11BFY25 $10.64B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$402.07B +7.8%	$372.81B +4.2%	$357.78B +10.9%	$322.47B +10.4%	$292.11B +8.7%	$268.71B
Net Income	$1.77B -61.7%	$4.61B -44.7%	$8.34B +93.6%	$4.31B -46.1%	$8.00B +11.5%	$7.18B
Operating Income	$4.66B -45.3%	$8.52B -38.0%	$13.74B +72.8%	$7.95B -40.2%	$13.31B -4.3%	$13.91B
EPS (Diluted)	$1.39 -62.0%	$3.66 -43.4%	$6.47 +98.5%	$3.26 -45.8%	$6.02 +10.3%	$5.46
Total Assets	$253.54B +0.1%	$253.22B +1.4%	$249.73B +9.4%	$228.28B -2.0%	$233.00B +1.0%	$230.72B
Total Debt	$64.57B -2.6%	$66.27B +7.6%	$61.61B +17.9%	$52.25B -7.0%	$56.18B -13.1%	$64.65B
Operating Cash Flow	$10.64B +16.8%	$9.11B -32.2%	$13.43B -17.0%	$16.18B -11.4%	$18.27B +15.1%	$15.87B

AI Insight: CVS Financial Trends

CVS delivered strong revenue growth from $91.2B to $100.4B over two years, but profitability remains volatile with Q3 2025 posting a $4.0B loss.

• Revenue grew consistently from $91.2B in Q2 2024 to $100.4B in Q1 2026, representing 10% growth over eight quarters.

• Total debt declined from $66.4B in Q2 2024 to $63.1B in Q1 2026, reducing leverage by $3.3B.

• Operating income turned volatile, swinging from $3.0B in Q2 2024 to -$3.2B loss in Q3 2025 before recovering to $4.7B.

⚠ Net income volatility persists with massive $4.0B loss in Q3 2025 creating earnings uncertainty despite recent recovery.

⚠ Operating cash flow showed negative $745M in Q3 2024, signaling potential working capital or operational challenges to monitor.

AI Insight: CVS Ratio Trends

CVS Health shows strong recovery with Q1 2026 operating margin hitting 4.7% and ROIC surging to 13.3%, but erratic quarterly volatility remains concerning.

• Operating margin rebounded sharply from -3.1% in Q3 2025 to 4.7% in Q1 2026.

• ROIC recovered dramatically from -9.2% in Q3 2025 to 13.3% in Q1 2026.

• Debt-to-equity ratio improved from 0.90 in Q3 2025 to 0.81 in Q1 2026.

• TTM operating margin compressed to 1.5% versus 3.6% quarterly performance in Q1 2025.

⚠ Extreme quarterly volatility with Q3 2025 showing negative margins across all profitability metrics.

⚠ Large gap between strong Q1 2026 quarterly metrics and weaker TTM performance suggests inconsistent execution.

Get alerted when CVS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CVS HEALTH Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CVS

BlackRock, Inc.
$9.0B125,919,853 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.9B82,650,076 sh
Capital World Investors
$5.5B77,248,642 sh
STATE STREET CORP
$4.3B59,322,181 sh
DODGE & COX
$3.7B51,780,116 sh
FMR LLC
$2.2B31,196,890 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.1B29,459,042 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.9B25,997,348 sh
Invesco Ltd.
$1.8B25,138,946 sh
WELLINGTON MANAGEMENT GROUP LLP
$1.6B22,567,732 sh

Fund	Value	Shares
BlackRock, Inc.	$9.0B	125,919,853
VANGUARD CAPITAL MANAGEMENT LLC	$5.9B	82,650,076
Capital World Investors	$5.5B	77,248,642
STATE STREET CORP	$4.3B	59,322,181
DODGE & COX	$3.7B	51,780,116
FMR LLC	$2.2B	31,196,890
GEODE CAPITAL MANAGEMENT, LLC	$2.1B	29,459,042
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.9B	25,997,348
Invesco Ltd.	$1.8B	25,138,946
WELLINGTON MANAGEMENT GROUP LLP	$1.6B	22,567,732

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CVS on your watchlist

Track score changes the day CVS HEALTH Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CVS a good stock to buy?

13F Pro's AI-powered analysis of CVS HEALTH Corp (CVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVS are available on the CVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CVS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CVS HEALTH Corp's investment landscape.